Phase I clinical trial initiated for monoclonal antibody combination for the prevention and treatment of COVID-19
First participants dosed in trial of AZD7442 to assess safety, tolerability and pharmacokinetics of the combinationThe first participants have been dosed in a Phase I trial of AZD7442, a combination of two monoclonal antibodies (mAbs) in development for the prevention and treatment of COVID-19. The trial, called NCT04507256, will evaluate the safety, tolerability and pharmacokinetics of AZD7442.[1] The trial will include up to 48 healthy participants in the UK aged 18 to 55 years and is funded by the Defense Advanced Research Projects Agency (DARPA), part of the US Department of Defense,